This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
RET Fusion Positive
First Diagnosis and Treatment
Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
You may not be if
\- Patients received antitumor treatment before
Patients with contraindication of chemotherapy
Pregnant or breast feeding women
Clareo Health | Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial
